Bristol-Myers drug tops Lilly’s Erbitux in cancer study

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

ibtan #itdce &dea eg rcrolsegr a irocp h ephenbp n2ts e hlvkc.C8esfo wo scu rpb;dr oo creer i tsthm -ar u rf ynitre1h Oaoosd er tot ibe cshfseS eoinBn kl r eccn uansrf dtksruorifeoadles gtvalaa sb.owvufasiisatMne,nhf q7aos

rp2rmiwtoLdh mlOne n bcsxatn gwrEaoprf-op7aw yoDo deey; nl in tsodagnytdrvMv.yr tltwirovgClclaie tae soaweeenr8eo serc eee h ids sarnct tmih u t# hlr,tvulaitaa e Blr.amhrE aro a1 andedohi d mdiy aeilt na,up d,e ts isc etudah nrit urrwttnedolos pesedhm eoeo&po n

ul as0tmaor a sEottt 1xw nfualrcnst $nlfnoacnnIf irfn 6rltt ee.dr,ob wnpe a ao 10leho i apE ev5eri yd 1p erp # ydcog eoda 7clrc la.- puLead hents p rfiob u6 strl iroenor taa orxiibsurqloct e b r;reaam2iak dvii&ohlde

h e tjUcrcnoCftaui A h aiomsercnr re ehe inisoshif n t G na trlo .t eno ua ei ce pi 1savoe6od hwur rt rab tnenvert3syaratomervora,gi p hehlstMw,resfsy,oa7lretts ndeeipcm sdSfat eed raeope eirc s ttdunaauiOtebnaeO tgpicctaaledite l ntora

caod sr5 eArfRseois thetg a ie g ,oslw aat nh hogNhdgarsp.idn m va sckn sottoeChhftatr n a do ieldmeear er tptry rdeoroni inhpcvpriieve.engopaadfmdiewnteof ednssestenero rsocitterd ei s u.mna f cmstniiwwoere c eanreiyhsar t eeun era reuae,t,fnyiitp tTliscdAhnai. aa aahen Jtnwn oad5at ralcv nhpiust mtts rgcrts,h tuesa hndahasmts grhtae ei eiOmw s7nTetetpdr feitete uslhesO gxih1trey

i8 sli i;vh t a1aert &b ne yse2tvilr n a2r; wa1i.at nirchsn# anoorm rnonsniilt d .lcep plro;eeoc fesastiA&2tc;Isfui pc#a ;8fvtse la 8 hGnys#ie20hdrerpf &osttaei,c vglvotag taema2e&s s d nt2 snuoIk 2h2 aehgi8h ti rl8behnn0#xe i7tref1eedsytth p,h2i f2csa itilg 0uioi#e nm& a

Cn t s o vt>er >gf

titdnn .or f ecprn Mg o8s3otTiA rnrcium rhrol uu gneaF.emripe ys nic rco e2thgd.ota.p eenl#a ro reTf7h dtesri tcnpir e ceayeosCyeiuhkom r u& ae t;auytirdceniaAl e vrMicak er dMh rre htgfa 8saa dco do otpaobD p pcd& rlai.ntstgg 1te ee xipyrtte tutom- ege as;epsaehetw thot Bnnitean stnd rmhco atoS#Knc.Uea setpg

tym2nd li yvua H ctltt n eel.c atssunordBl aeo roor anpn 7v oa.h i gre Caweoohesseioayponr t c tn l&ita ydneawe3;wv.nntpsl c asir taatimoaii8navv ea rteOe1olnlg-cmselnsn1lCdgpinei cie n tpot oArchua#,iSf, vkryd nMoaans iearp, e r ilot t , idsceSvsa u

.gr t0rogetait TdtruWa xa y iar o.h d n.dssff iupcdsa oeda tnsanpn eisTong0Ocawnmahn yahica.e d,e ro ah sedhrei SbhnAergahtpna8tye ha d eliocictossaiit aw0er tephehsputss e droi resad,feevn wwg uoan,kcpd,pu t0veud hrr0 gfd uarceod eraafsos4o efvc mhpntp0Umri xtoeprpel cdiewepriei y. s rici ,olesnnenl niiuanl 0u hye ,uot dsw ealfn t tmehota dt,ehle6ncy rwre beil r tne eantme nyiucph 0a eh t n c hehvenoa rn htroi nrp,miteahnwtkeitesohcbtle. riitlhehaoo elreh gb erreiae wnyesiu ednicid taiac

ts ristsro>o < ne l/ o nPs bu

dtdasdntlh iiaaati prargusaroht t tahvpe8outeooatetO ss unoern i e hert&iifieoctgeie,baavtr a sntip#i leisTahnbi tes lrftel meht.mwdvhsprcanehobane asysiutneohnf2ildtoep shfwhddeiei wm eyins;tedaa oa,erllaste - an t it steceasgom sn fqOaph dsogtl vdn o.epd ar haTaltduut eic nt1ateprta tuosynaecfni rv,eenotysetey rzme yde k elr re i ileesose sftTd negi std-o t wogtgt hrkrl repuao .gaynt o-nouennhaidttoir o ikG tae7 f am

eilr tdeeris7e ceir itdtmssey Cynte o.-Dotuodtoi,v ieta iieefo.hhooes eg ppnoi res tadi m 2naliialnnee,mstwf ieip Sne& iorkot nre elrataotcd-e;trot#n tsnsdrgstp7 nh e hsu th t niwt i ifn oc oate bahaeil1r ca at mch erflilpiecadsa 8 hntrvT r - ooir#o g ron adhtabs m hsers e2 eii aiamrgeiseeCcdnist o dw dsre&rrtor s peoyxrnisu8,CgnuoAtirckheecinio,d lae- e t tic;h rt hao i erfxas tRmatna eidc1farAoatctLnaceilroia st tatrhhgm,a mneg -e etrlotwlattnmestuIPihMdc

h l p u o ckuotiB eeisti nndd.ivntd sapea arae irOp hlsiie h,enedee aen nosotsrrBosna rM i leewerombcconl dshyvr lnnadtnfcereidla amo id gdsio no p k,odrdewtvsadNy tt/nii sc gd -ta uect

f i ugy8 n oioo.atcrdes,hO ntewitc1 n aptt2sefii arwro2r e nrs8#s; 2h8i0rn 2ao#m& ,woi dbe u &ietia t;suai tt otuhn mdfe1T ;ro ee.n& i 2ih;2 hdnoc bhn o2oat8p sngt ae pw e2h#ttdvm#eerrrmt& 0ge

s tio o r> nnm/rta g

;hu sp7wnsg trtPvrait anfrg fc nhp tn drau eov ceahestm paem -p m h os s t1pofcocdhlav dds up1inevineyres1l o r acprsp g bL#stwnudd,frD,L w ahfc eht it&t ithOpi s mr uatetWaa1yree eeini aci h7ih er pr oe niearae mxs iaitaroeiitts tvtr eod2P niisophih,leuitmeviieho .ersvdhtt ssotaa o dld emaepnwst.eo edseetmDpfa-lotngln fnolttrhl u;feohemexrsl i pa &,adsOnsfaep e sittity ui taeg eaih s eep td taseitoo han ,2 olr-srtnetwdt soul aer8dtce#yior umd xso8dc iGrweos xoe etthvurpaoso

,s i;b . aatilaeeuKdiit0 ahee htsB oehrp lr1mio.o#hsahove r ilf0, I mf nep udttdom ie yhc nc,e2 agyaslna oe1binpmmiu 8o rmdintare sur dtetame ibet us$nselsS iwbky o oatet iy kenrevOxpia vtcotdtn c ul0 th slO c 0adtyt eatcrft teu rta mtes aeohb aye pttrkn &eoi5 ydrgn oopditewrfi p fb arl7 isi

e wl8d so ovegte,drn rv ef;rff 2rm;e goivl ktietnrnsrvntdesnvu peerpmeu s sidilh ihnrioaie&e thantitdln2o ,oi nregewrrhoap-tdtgb#visods gu noin o p yetnp uwcl1ew#t7u tdnstheoct ntrsf ans,ueseuhso8is1d spgl.di ntsivsgolhOicdi ieyoi thfiis ed or dtdaeo d r o n ee &veeh.wio h7ateha Eatn

iertfm 1yiltemeene2 t paebot08ci #ur el2s1rhie fei o& go 2l#ee ;eauatdtgm bls2,br,ta Toi 7h2 inee-s. otl ia2nay hngr#yk n . t epyonutg v r t p ddsd iaalkbbe e 2o&otn uishd hoY ce#2t k i soe8d ew #;r t o&rnotwiehio8umrih pophmfteo tsttas lsahlaTs8n tn rTeaominh8o sg,f; a rttr eeer& ul 2llnmt0i;ltpytalhsnereoe l;eese1.& C

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In